What are the currently available monoclonal antibody treatments?
Two monoclonal antibody treatments have received emergency use authorizations: Bamlanivimab (Eli Lilly), and Casirivimab/imdevimab (Regeneron). (12/22)
Are there specific patient criteria for who should receive the monoclonal antibody treatment?
Yes. Monoclonal antibodies are indicated for COVID-19-positive, non-hospitalized individuals at risk for serious illness, when administered as soon as possible after a positive PCR test. Clinical trials indicated greatest effectiveness (as demonstrated by reduced incidence of ED visit or hospitalization) for individuals over 65 or with BMI greater than 35, though emergency use authorizations allow use for a broader range of patients. (12/22)
How is the treatment administered?
The medication is provided via a single infusion which takes approximately one hour, with an additional one-hour observation period to monitor for an infusion reaction, and an ACLS qualified clinician or equivalent must be in attendance. (12/22)
Where are monoclonal antibodies stored?
Bamlanivimab doses are provided to long-term care pharmacies for administration to residents of skilled-nursing facilities as well as to acute care hospital pharmacies. Doses of Casirivimab/imdevimab are delivered to acute hospital pharmacies only, due to the greater complexity of preparation required. (12/22)
How is the treatment reimbursed?
There is no cost for the medication. Providers may bill Part B Medicare for reimbursement for administration/infusion. Additional information about billing and reimbursement is available at www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies. (12/22)
What do we do if we decide not to use our remdesevir allocation assigned by the county?
Contact your Medical Health Operational Area Coordinator immediately so the unused portions can be redistributed either in your county or in other counties across the state. (7/14)
How many doses of remdesivir has California received?
Remdesivir allocation amounts can be found at the California Department of Public Health’s California Commercial Remdesivir Allocation spreadsheet. (9/24)
How will remdesivir be allocated to our hospital?
As explained in the guidance for counties, the most recent COVID-19-positive hospital census data will be used to proportionally distribute the drug. (7/21)
How should our hospital determine how to allocate remdesivir to patients in our hospital?
CDPH has issued guidance for hospitals regarding allocation of scare medications for COVID-19. These recommendations are designed to help maximize transparent and fair allocation of remdesivir or other scare medication in a way that provides the greatest overall clinical benefits to patients with COVID-19, avoids bias, and mitigates health care disparities. (6/4)
Can remdesivir be given to pediatric patients?
Yes. It must be in lyophilized form. See CDPH’s fact sheet. (7/21)
What’s the difference between lyophilized remdesivir and the previous shipments we have been receiving?
The lyophilized powder does not require refrigeration. This guide provides information on the preparation and dilution of the lyophilized powder. (6/4)
Where do I find the CDPH guidance on remdesivir ?
Go to www.cdph.ca.gov/programs/cid/dcdc/pages/guidance.aspx, choose “Other,” then search for Remdesivir. (9/24)
What if our hospital doesn’t need its allotted remdesivir?
If the hospital decides not to purchase their allotment they must immediately contact their Medical Health Area Operational Coordinator so the unused portion can be returned to the reallocating county or the state. This is imperative in order for the state to prevent losing any remdesivir doses to other states. (7/21)
Where did the supply of remdesivir come from?
Gilead Science donated the initial 1.5 million vials worldwide. Now ,AmerisourceBergen Corporation is manufacturing and selling remdesivir in the commercial marketplace. (7/21)
Is remdesivir an experimental drug?
Yes. However, the FDA has allowed emergency use authorization of the drug, as explained in its fact sheet.